The company’s RNA-based systems enable the precise control of gene therapies even after dosing, meaning they can respond to and reduce their own side effects.
Concinnity has raised €3.6M across 1 funding round from 4 investors, most recently a Seed round in Dec 2024. Based in Edinburgh, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-12-16 | Seed | €3.6M |
| Eos Advisory,Maven Capital Partners,Old College Capital (OCC) - the University of Edinburgh’s in-house venture investment fund,Scottish Enterprise |
| View deal → |
